BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.08
+1.32 (1.77%)
At close: Sep 9, 2026, 4:00 PM EDT
76.05
-0.03 (-0.04%)
After-hours: Sep 9, 2026, 7:48 PM EDT
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $14.87 billion as of September 9, 2026. Its market cap has increased by 43.31% in one year.
Market Cap
14.87B
Enterprise Value
17.53B
1-Year Change
43.31%
Ranking
Category
Stock Price
$76.08
ChartMarket Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $14.87B, an increase of 348.02%. That is a compound annual growth rate of 23.13%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 9, 2026 | 14.87B | 0.90% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ascendis Pharma | 17.61B |
| Jazz Pharmaceuticals | 15.73B |
| Exelixis | 14.57B |
| Summit Therapeutics | 13.89B |
| BioMarin Pharmaceutical | 12.68B |
| Madrigal Pharmaceuticals | 12.42B |
| Corcept Therapeutics | 12.26B |
| Halozyme Therapeutics | 12.23B |